ArticleFrontiers in medicine2026
Electroacupuncture for trigeminal neuralgia with anxiety disorders: study protocol for a randomized controlled trial.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Trigeminal neuralgia (TN) is extremely vulnerable to inducing anxiety disorders in TN patients owing to the severe intensity of pain and recurrent episodes. The efficacy of the routine management of TN with anxiety disorders is still unsatisfactory. Acupuncture has been widely utilized in the treatment of TN for many years; however, the effectiveness of Electroacupuncture (EA) for TN with anxiety disorders remains uncertain. Therefore, this randomized, controlled, single-blinded trial was designed to investigate the efficacy and safety of EA for TN with anxiety disorders. Methods: This single-center, prospective, randomized controlled trial will recruit 60 TN patients with anxiety. All patients will be randomly assigned to the EA or sham EA group in a 1:1 ratio via a computerized central randomization system. The total trial duration is 18 weeks, including a 2-week baseline phase, a 4-week treatment phase, and a 12-week follow-up phase. Participants who meet the inclusion criteria will receive active EA or sham EA treatment for 60 min, three times a week, for 4 weeks. Planned Outcomes: The primary outcome is the change of Beck Anxiety Inventory score and Visual Analog Scale score from baseline, while the BPI-Facial scores will be regarded as the secondary outcomes. All adverse effects will also be assessed during the study period. Outcome measures will be assessed at pre-intervention, post-intervention (week 4), and at the end of follow-up (week 16). Trial Registration: Chinese Clinical Trial Registry: ChiCTR2300079048. This study was registered on December 25, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.